|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Performance of the Montreal classification for inflammatory bowel diseases显示文摘AIM:To validate the Montreal classification system for Crohn's disease(CD) and ulcerative colitis(UC) within the Netherlands.METHODS:A selection of 20 de-identified medical records with an appropriate representation of the inflammatory bowel disease(IBD) sub phenotypes were scored by 30 observers with different professions(gastroenterologist specialist in IBD,gastroenterologist in training and IBD-nurses) and experience level with IBD patient care.Patients were classified according to the Montreal classification.In addition,participants were asked to score extra-intestinal manifestations(EIM) and disease severity in CD based on their clinical judgment.The inter-observer agreement was calculated by percentages of correct answers(answers identical to the 'expert evaluation') and Fleiss-kappa(k).Kappa cutoffs:< 0.4-poor; 0.41-0.6-moderate; 0.61-0.8-good; > 0.8 excellent.RESULTS:The inter-observer agreement was excellent for diagnosis(k = 0.96),perianal disease(k = 0.92) and disease location in CD(k = 0.82) and good for age of onset(k = 0.67),upper gastrointestinal disease(k = 0.62),disease behaviour in CD(k = 0.79) and disease extent in UC(k = 0.65).Disease severity in UC was scored poor(k = 0.23).The additional items resulted in a good inter-observer agreement for EIM(k = 0.68) and a moderate agreement for disease severity in CD(k = 0.44).Percentages of correct answers over all Montreal items give a good reflection of the inter-observer agreement(> 80%),except for disease severity(48%-74%).IBD-nurses were significantly worse in scoring upper gastrointestinal disease in CD compared to gastroenterologists(P = 0.008) and gastroenterologists in training(P = 0.040).Observers with less than 10 years of experience were significantly better at scoring UC severity than observers with 10-20 years(P = 0.003) and more than 20 years(P = 0.003) of experience with IBD patient care.Observers with 10-20 years of experience with IBD patient care were significantly better at scoring upper gastrointestinal disease in CD than observers with less than 10 years(P = 0.007) and more than 20 years(P = 0.007) of experience with IBD patient care.CONCLUSION:We found a good to excellent interobserver agreement for all Montreal items except for disease severity in UC(poor). | Lieke M Spekhorst Marijn C Visschedijk Rudi Alberts Eleonora A Festen Egbert-Jan van der Wouden Gerard Dijkstra Rinse K Weersma | 2014 | World Journal of Gastroenterology2014，20，41： | 4 |
| 2 | Predicting(side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics显示文摘Inflammatory bowel disease (IBD) is a chronic and heterogeneous intestinal inflammatory disorder. The medical management of IBD aims for long-lasting disease remission to prevent complications and disease progression. Early introduction of immunosuppression forms the mainstay of medical IBD management. Large inter-individual variability in drug responses, in terms of both efficacy and toxicity, leads to high rates of therapeutic failure in the management of IBD. Better patient stratification is needed to maximize patient benefit and minimize the harm caused by adverse events. Pre-treatment pharmacogenetic testing has the potential to optimize drug selection and dose, and to minimize harm caused by adverse drug reactions. In addition, optimizing the use of cheap conventional drugs, and avoiding expensive ineffective drugs, will lead to a significant reduction in costs. Genetic variation in both TPMT and NUDT15, genes involved in thiopurine metabolism, is associated to an increased risk of thiopurine-induced myelosuppression. Moreover, specific HLA haplotypes confer risk to thiopurine-induced pancreatitis and to immunogenicity to tumor necrosis factor-antagonists, respectively. Falling costs and increased availability of genetic tests allow for the incorporation of pre-treatment genetic tests into clinical IBD management guidelines. In this paper, we review clinically useful pharmacogenetic associations for individualized treatment of patients with IBD and discuss the path from identification of a predictive pharmacogenetic marker to implementation into IBD clinical care. | Michiel Dirk Voskuil Amber Bangma Rinse Karel Weersma Eleonora Anna Margaretha Festen | 2019 | World Journal of Gastroenterology2019，25，21： | 2 |
| 3 | Treatment of grade III and IV haemorrhoidal disease with PPH or THD. A randomized trial on postoperative complications and short-term results显示文摘 | Sebastiaan Festen M. J. Hoogstraten A. A. W. Geloven M. F. Gerhards | 2009 | International Journal of Colorectal Disease2009，，12： | 2 |
| 4 | How will insights from genetics translate to clinical practice in inflammatory bowel disease?显示文摘 | E.A.M. Festen R.K. Weersma | 2014 | Best Practice & Research Clinical Gastroenterology2014，，3： | 2 |
| 5 | 显示文摘 | Bootsma GP Dekhuijzen PN Festen J | 1997 | Neth J Med1997，50，6： | 1 |
| 6 | Treatment of fistulas in ano with fibrin glue显示文摘 | Gisbertz SS Sosef MN Festen S | 2005 | Dig Surg2005，22，： | 1 |
| 7 | The prevalence of Helicobact er pylori in peptic ulcer disease显示文摘 | Kuipers E J Thijs J C Festen H P | 1995 | Aliment Pharmacol Ther1995，9，： | 1 |
| 8 | Decline in older per- sons' ability to recognize speech in noise: the influence of de- mographic, health- related, environmental, and cognitive factors显示文摘 | Pronk M Deeg D Festen JM | 2013 | Ear Hear2013，34，： | 1 |
| 9 | High prevalence of central adrenal insufficiency in patients with Prader- Willi syndrome 显示文摘 | de Lind van Wijngaarden RF Otten B J Festen DA | 2008 | J Clin Endoerinol Metab2008，93，5： | 1 |
| 10 | CB&I Lummus and partners to turn LNG FPSO concept into a reality显示文摘 | Leo Festen Jos Leo Ron Vis | 2009 | LNG journal2009，，9： | 1 |
| 11 | Bronchial vagal tone and responsiveness to histamine,exercise and bronchodilators in adult patients with cystic fibrosis显示文摘 | Van Haren EHJ Lammers J-WJ Festen J | 1992 | Eur Respir J1992，5，9： | 1 |
| 12 | Fractures of the lateral hu- meral condyle in children: late results 显示文摘 | van Vugt AB Severijnen RV Festen C | 1988 | Arch Orthop Trauma Surg1988，107，： | 1 |
| 13 | Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy显示文摘 | Festen DA van Toorenenbergen A Duivenvoorden H J | 2007 | J Clin Endocrinol Metab2007，92，4： | 1 |
| 14 | Genetic analysis of in- nate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP 显示文摘 | Zhemakova A Festen E M Franke L | 2008 | American Human Genetics2008，82，5： | 1 |
| 15 | Effect of short and long-term treatment with omeprazole on the absorption and serum levels of cobalamin显示文摘 | Schenk BE Festen HPM Kuipem EJ | | 0，，： | 1 |
| 16 | Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis显示文摘 | WESDORP IC DEKKER W FESTEN HP | 1993 | Dig Dis Sci1993，38，12： | 1 |
| 17 | A meta-analysis of ge- nome-wide association scans identifies IL18R'AP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease 显示文摘 | Festen E A M Goyette P Green T | 2011 | PLoS Genetics2011，7，10： | 1 |
| 18 | Perianal abscess and fistula in ano in infants显示文摘 | Festen C Harten H | 1998 | J Pediatr Surg1998，33，： | 1 |
| 19 | Perianal abscess and fistula-in-ano in infants显示文摘 | Festen C van Harten H | 1998 | J Pediatr Surg1998，，33： | 1 |
| 20 | Evaluationof a wide range of amplitude-frequency responses for the heating irrlpaired显示文摘 | Van Buuren RA Festen JM Plomp R | 1995 | J Speech Hear Res1995，38，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员